Lornoxicam (Tablets, Lyophilisate) Instructions for Use
ATC Code
M01AC05 (Lornoxicam)
Active Substance
Lornoxicam (Rec.INN registered by WHO)
Clinical-Pharmacological Group
NSAID
Pharmacotherapeutic Group
Anti-inflammatory and antirheumatic drugs; non-steroidal anti-inflammatory and antirheumatic drugs; oxicams
Pharmacological Action
NSAID, belongs to the oxicam class. It has a pronounced anti-inflammatory and analgesic effect, and also possesses antipyretic and antiplatelet action.
The mechanism of action is associated with the suppression of inflammatory factors; inhibition of prostaglandin synthesis due to the inhibition of COX1 and COX2, which leads to a disruption of arachidonic acid metabolism and inhibition of prostaglandin synthesis both at the site of inflammation and in healthy tissues. It suppresses the exudative and proliferative phases of inflammation.
Pharmacokinetics
Lornoxicam is rapidly and completely absorbed from the gastrointestinal tract after oral administration and from the injection site after intramuscular injection. Cmax in plasma is reached approximately 1-2 hours after oral administration and 15 minutes after intramuscular administration.
The absolute bioavailability is 90-100%.
Plasma protein binding is 99% and does not depend on the concentration of the active substance.
Lornoxicam is completely metabolized. It is present in the blood plasma mainly in the unchanged form and, to a lesser extent, as a hydroxylated metabolite, which has no pharmacological activity.
The T1/2 averages 4 hours and does not depend on the concentration of lornoxicam. Approximately one-third of its metabolites are excreted by the kidneys and two-thirds through the liver.
No significant changes in the pharmacokinetic parameters of lornoxicam were found in the elderly, as well as in patients with renal or hepatic insufficiency.
Indications
Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, joint syndrome during gout exacerbation, bursitis, tenosynovitis.
Moderate and severe pain syndrome (including arthralgia, myalgia, neuralgia, lumbago, sciatica, migraine, toothache and headache, algodysmenorrhea, pain from injuries, burns). Febrile syndrome (in colds and infectious diseases).
ICD codes
| ICD-10 code | Indication |
| K08.8 | Other specified disorders of teeth and supporting structures (including toothache) |
| M05 | Seropositive rheumatoid arthritis |
| M10 | Gout |
| M13.9 | Arthritis, unspecified |
| M15 | Polyosteoarthritis |
| M19.9 | Unspecified arthrosis |
| M25.5 | Pain in joint |
| M42 | Spinal osteochondrosis |
| M45 | Ankylosing spondylitis |
| M54.1 | Radiculopathy |
| M54.3 | Sciatica |
| M54.4 | Lumbago with sciatica |
| M65 | Synovitis and tenosynovitis |
| M70 | Soft tissue disorders related to use, overuse, and pressure |
| M71 | Other bursopathies |
| M79.1 | Myalgia |
| M79.2 | Neuralgia and neuritis, unspecified |
| N94.4 | Primary dysmenorrhea |
| N94.5 | Secondary dysmenorrhea |
| R50 | Fever of unknown origin |
| R51 | Headache |
| R52.0 | Acute pain |
| R52.2 | Other chronic pain |
| ICD-11 code | Indication |
| 8A8Z | Headache disorders, unspecified |
| 8B93.Z | Radiculopathy, unspecified |
| 8E4A.1 | Paraneoplastic or autoimmune diseases of the peripheral or autonomic nervous system |
| DA0A.Z | Diseases of teeth and supporting structures, unspecified |
| FA05 | Polyosteoarthritis |
| FA0Z | Osteoarthritis, unspecified |
| FA20.0 | Seropositive rheumatoid arthritis |
| FA25 | Gout |
| FA2Z | Inflammatory arthropathies, unspecified |
| FA85.Z | Defects of vertebral end-plates, unspecified |
| FA92.0Z | Ankylosing spondylitis, unspecified |
| FB40.Z | Tenosynovitis, unspecified |
| FB50.1 | Bursitis associated with use, overuse or pressure |
| FB50.Z | Bursitis, unspecified |
| FB56 | Specified soft tissue diseases, not elsewhere classified |
| FB56.2 | Myalgia |
| GA34.3 | Dysmenorrhea |
| LA30.5Z | Anomalies of tooth resorption or loss, unspecified |
| ME82 | Pain in joint |
| ME84.20 | Lumbago with sciatica |
| ME84.3 | Sciatica |
| MG26 | Fever of other or unknown origin |
| MG30.Z | Chronic pain syndrome, unspecified |
| MG31.Z | Acute pain, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Tablets, Lyophilisate
When taken orally – 4 mg 2-3 times/day or 8 mg 2 times/day.
IV or IM initial dose – 8-16 mg. If the analgesic effect is insufficient at a dose of 8 mg, an additional 8 mg can be administered.
Maximum daily doses when taken orally – 16 mg; for concomitant gastrointestinal diseases, impaired renal or liver function, elderly patients (over 65 years), with body weight less than 50 kg, as well as after extensive surgery – 12 mg in 3 divided doses.
Adverse Reactions
From the digestive system abdominal pain, diarrhea, dyspepsia, nausea, vomiting, heartburn, diarrhea; rarely – flatulence, dry mouth, gastritis, esophagitis, erosive and ulcerative lesions of the gastric and intestinal mucosa, gastrointestinal bleeding (including rectal), impaired liver function.
From the CNS rarely – dizziness, headache, drowsiness, agitation, sleep disorders, depression, tremor, aseptic meningitis.
From the hematopoietic system rarely – leukopenia, thrombocytopenia, agranulocytosis.
From the blood coagulation system with long-term use in high doses – bleeding (gastrointestinal, gingival, uterine, nasal, rectal, hemorrhoidal), anemia.
From metabolism rarely – increased sweating, chills, change in body weight.
From the cardiovascular system rarely – arterial hypertension, tachycardia, development or worsening of heart failure.
From the urinary system rarely – dysuria, decreased glomerular filtration, interstitial nephritis, glomerulonephritis, papillary necrosis, nephrotic syndrome, peripheral edema, acute renal failure.
Allergic reactions skin rash, itching, urticaria, angioedema, bronchospasm.
Other edematous syndrome, tinnitus, change in body weight.
Contraindications
Acute gastrointestinal bleeding, peptic ulcer of the stomach and duodenum in the acute phase, ulcerative colitis in the acute phase, bronchial asthma, severe chronic heart failure, hypovolemia, blood coagulation disorders (including hemophilia, hemorrhagic diathesis, thrombocytopenia), severe hepatic and/or renal failure, glucose-6-phosphate dehydrogenase deficiency, cerebral hemorrhage (including suspected), pregnancy, lactation period, children and adolescents under 18 years of age, hypersensitivity to lornoxicam, acetylsalicylic acid or other NSAIDs.
Use in Pregnancy and Lactation
Lornoxicam is contraindicated for use during pregnancy and during the lactation (breastfeeding) period.
Use in Hepatic Impairment
Contraindicated in severe hepatic insufficiency.
In case of impaired liver function, Lornoxicam should be used only after a thorough assessment of the expected benefit of therapy and the possible risk.
Use in Renal Impairment
Contraindicated in severe renal insufficiency.
In case of mild impairment of renal function (serum creatinine level 150-300 µmol/L), Lornoxicam should be used only after a thorough assessment of the expected benefit of therapy and the possible risk. Use with caution in moderate renal insufficiency.
In patients with impaired renal function, regular monitoring of their function is necessary during treatment.
Pediatric Use
Contraindicated in children and adolescents under 18 years of age.
Geriatric Use
Use with caution in elderly patients (over 65 years).
Elderly patients should have their blood pressure monitored when using lornoxicam.
Special Precautions
Use with caution in case of erosive and ulcerative lesions and gastrointestinal bleeding (in history), moderate renal insufficiency, conditions after surgical interventions, in elderly patients (over 65 years), in patients with body weight less than 50 kg.
Lornoxicam should be used only after a thorough assessment of the expected benefit of therapy and the possible risk in the following cases: mild degree of renal impairment (serum creatinine level 150-300 µmol/L); heart failure and other conditions accompanied by a decrease in circulating blood volume and renal blood flow; impaired liver function; arterial hypertension and conditions accompanied by fluid retention, edema; patients who have undergone extensive surgery.
In patients with impaired renal function, regular monitoring of renal function is necessary during treatment.
Elderly patients, as well as patients with arterial hypertension, should have their blood pressure monitored when using lornoxicam.
For gastric peptic ulcer and duodenal ulcer disease, therapy should be carried out against the background of simultaneous administration of histamine H2-receptor blockers or omeprazole.
With long-term use, it is necessary to periodically monitor the peripheral blood picture, as well as indicators of liver and kidney function.
Effect on ability to drive vehicles and operate machinery
Since Lornoxicam reduces the speed of psychomotor reactions, special care should be taken when driving a car and engaging in other potentially hazardous activities during the period of use.
Drug Interactions
With simultaneous use with anticoagulants, platelet aggregation inhibitors, an increase in bleeding time and an increased risk of bleeding are possible.
With simultaneous use, the hypotensive effect of beta-blockers and ACE inhibitors is reduced.
With simultaneous use, the hypoglycemic effect of sulfonylurea derivatives is enhanced.
With simultaneous use, the diuretic and hypotensive effect of diuretics is reduced.
With simultaneous use with NSAIDs, the risk of side effects increases; with digoxin – the renal clearance of digoxin decreases; with methotrexate – the concentration of methotrexate in the blood plasma increases; with cimetidine – the concentration of lornoxicam in the blood plasma increases; with lithium salts – an increase in the Cmax of lithium in the blood plasma is possible, which leads to an increase in the manifestations of side effects of lithium preparations.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Film-coated tablets, 4 mg: 10, 20, 25, 30, 40, 50, 60, 75, 90, 100, 120, 125, 150, 200, or 250 pcs.
Film-coated tablets, 8 mg: 10, 20, 25, 30, 40, 50, 60, 75, 90, 100, 120, 125, 150, 200, or 250 pcs.
Marketing Authorization Holder
Atoll LLC (Russia)
Manufactured By
Ozon, LLC (Russia)
Dosage Forms
 |
Lornoxicam | Film-coated tablets, 4 mg: 10, 20, 25, 30, 40, 50, 60, 75, 90, 100, 120, 125, 150, 200, or 250 pcs. |
| Film-coated tablets, 8 mg: 10, 20, 25, 30, 40, 50, 60, 75, 90, 100, 120, 125, 150, 200, or 250 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets yellow with a greenish tint, round, biconvex; on the cross-section of the tablets, a core of yellow with a greenish tint and a film coating are visible.
| 1 tab. | |
| Lornoxicam | 4 mg |
Excipients : lactose monohydrate (milk sugar) – 45 mg, microcrystalline cellulose (MCC-101) – 42.5 mg, croscarmellose sodium – 5 mg, povidone K25 – 2.5 mg, magnesium stearate – 1 mg.
Coating composition hypromellose – 1.65 mg, titanium dioxide – 0.75 mg, macrogol-4000 – 0.45 mg, talc – 0.12 mg, quinoline yellow dye – 0.03 mg.
10 pcs. – contour cell packs – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
25 pcs. – contour cell packs – cardboard packs.
25 pcs. – contour cell packs (2) – cardboard packs.
25 pcs. – contour cell packs (3) – cardboard packs.
25 pcs. – contour cell packs (4) – cardboard packs.
25 pcs. – contour cell packs (5) – cardboard packs.
30 pcs. – contour cell packs – cardboard packs.
30 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – contour cell packs (3) – cardboard packs.
30 pcs. – contour cell packs (4) – cardboard packs.
30 pcs. – contour cell packs (5) – cardboard packs.
50 pcs. – contour cell packs – cardboard packs.
50 pcs. – contour cell packs (2) – cardboard packs.
50 pcs. – contour cell packs (3) – cardboard packs.
50 pcs. – contour cell packs (4) – cardboard packs.
50 pcs. – contour cell packs (5) – cardboard packs.
Film-coated tablets yellow with a greenish tint, round, biconvex; on the cross-section of the tablets, a core of yellow with a greenish tint and a film coating are visible.
| 1 tab. | |
| Lornoxicam | 8 mg |
Excipients : lactose monohydrate (milk sugar) – 90 mg, microcrystalline cellulose (MCC-101) – 85 mg, croscarmellose sodium – 10 mg, povidone K25 – 5 mg, magnesium stearate – 2 mg.
Coating composition hypromellose – 3.3 mg, titanium dioxide – 1.5 mg, macrogol-4000 – 0.9 mg, talc – 0.24 mg, quinoline yellow dye – 0.06 mg.
10 pcs. – contour cell packs – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
25 pcs. – contour cell packs – cardboard packs.
25 pcs. – contour cell packs (2) – cardboard packs.
25 pcs. – contour cell packs (3) – cardboard packs.
25 pcs. – contour cell packs (4) – cardboard packs.
25 pcs. – contour cell packs (5) – cardboard packs.
30 pcs. – contour cell packs – cardboard packs.
30 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – contour cell packs (3) – cardboard packs.
30 pcs. – contour cell packs (4) – cardboard packs.
30 pcs. – contour cell packs (5) – cardboard packs.
50 pcs. – contour cell packs – cardboard packs.
50 pcs. – contour cell packs (2) – cardboard packs.
50 pcs. – contour cell packs (3) – cardboard packs.
50 pcs. – contour cell packs (4) – cardboard packs.
50 pcs. – contour cell packs (5) – cardboard packs.
Film-coated tablets, 4 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 50, 56, 60, 70, 84, 100, or 140 pcs.
Film-coated tablets, 8 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 50, 56, 60, 70, 84, 100, or 140 pcs.
Marketing Authorization Holder
Lekvalis, LLC (Russia)
Manufactured By
Interpharma, LLC (Russia)
Dosage Forms
|
Lornoxicam | Film-coated tablets, 4 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 50, 56, 60, 70, 84, 100, or 140 pcs. |
| Film-coated tablets, 8 mg: 7, 10, 14, 20, 21, 28, 30, 35, 40, 42, 50, 56, 60, 70, 84, 100, or 140 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets from yellow to almost yellow with a brownish tint, round, biconvex. On the cross-section, the core is yellow.
| 1 tab. | |
| Lornoxicam | 4 mg |
Excipients : magnesium stearate – 2 mg, povidone K-30 – 5 mg, croscarmellose sodium – 10 mg, microcrystalline cellulose (type 101) – 85 mg, lactose monohydrate – 94 mg.
Film coating composition : Vycot WT-01883, yellow (hypromellose, polyethylene glycol 400, titanium dioxide, talc, polyethylene glycol 6000, aluminum quinoline yellow lake dye).
7 pcs. – contour cell packs (from 1 to 10 pcs.) – cardboard packs.
10 pcs. – contour cell packs (from 1 to 10 pcs.) – cardboard packs.
14 pcs. – contour cell packs (from 1 to 10 pcs.) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
100 pcs. – polymer jars (1) – cardboard packs.
Film-coated tablets from white to almost white, round, biconvex. The cross-section shows a yellow core.
| 1 tab. | |
| Lornoxicam | 8 mg |
Excipients: magnesium stearate – 2 mg, povidone K-30 – 5 mg, croscarmellose sodium – 10 mg, microcrystalline cellulose (type 101) – 85 mg, lactose monohydrate – 94 mg.
Film coating composition: Vicon WT-MP-2043, white (hypromellose, polyethylene glycol 3350, titanium dioxide, talc).
7 pcs. – contour cell packs (from 1 to 10 pcs.) – cardboard packs.
10 pcs. – contour cell packs (from 1 to 10 pcs.) – cardboard packs.
14 pcs. – contour cell packs (from 1 to 10 pcs.) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
100 pcs. – polymer jars (1) – cardboard packs.
Lyophilisate for preparation of solution for intravenous and intramuscular administration 8 mg: vial 5 pcs.
Marketing Authorization Holder
Moscow Endocrine Plant FSUE (Russia)
Manufactured By
Ferment Firm, LLC (Russia)
Dosage Form
|
Lornoxicam | Lyophilisate for preparation of solution for intravenous and intramuscular administration 8 mg: vial 5 pcs. |
Dosage Form, Packaging, and Composition
Lyophilisate for preparation of solution for intravenous and intramuscular administration in the form of a dense mass of yellow color.
| 1 vial | |
| Lornoxicam | 8 mg |
Excipients: mannitol (mannite) – 100 mg, trometamol – 12 mg, edetate disodium – 0.2 mg, sodium hydroxide – to pH 8.0-9.5.
8 mg – vials (5) – contour cell packs (1) – cardboard packs.
Film-coated tablets, 4 mg: 10, 20, 30, 50, or 100 pcs.
Film-coated tablets, 8 mg: 10, 20, 30, 50, or 100 pcs.
Marketing Authorization Holder
Pharmproekt, JSC (Russia)
Dosage Forms
|
Lornoxicam | Film-coated tablets, 4 mg: 10, 20, 30, 50, or 100 pcs. |
| Film-coated tablets, 8 mg: 10, 20, 30, 50, or 100 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets from yellow to bright yellow, round, biconvex; the cross-section shows a yellow core.
| 1 tab. | |
| Lornoxicam | 4 mg |
Excipients: lactose monohydrate, microcrystalline cellulose (type 102), croscarmellose sodium, povidone K30, magnesium stearate.
Film coating composition Opadry yellow (03F220150) [hypromellose (hydroxypropyl methylcellulose), titanium dioxide, talc, macrogol 6000, quinoline yellow dye].
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
Film-coated tablets from yellow to bright yellow, round, biconvex; the cross-section shows a yellow core.
| 1 tab. | |
| Lornoxicam | 8 mg |
Excipients: lactose monohydrate, microcrystalline cellulose (type 102), croscarmellose sodium, povidone K30, magnesium stearate.
Film coating composition Opadry yellow (03F220150) [hypromellose (hydroxypropyl methylcellulose), titanium dioxide, talc, macrogol 6000, quinoline yellow dye].
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
Lyophilisate for preparation of solution for intravenous and intramuscular administration 8 mg: amp. 5 pcs. or 10 pcs. in set with solvent or without it
Marketing Authorization Holder
Ellara, LLC (Russia)
Dosage Form
|
Lornoxicam | Lyophilisate for preparation of solution for intravenous and intramuscular administration 8 mg: amp. 5 pcs. or 10 pcs. in set with solvent or without it |
Dosage Form, Packaging, and Composition
Lyophilisate for preparation of solution for intravenous and intramuscular administration in the form of a powder or dense mass of yellow color; solvent (in case of packaging with solvent) – transparent colorless liquid without odor; reconstituted solution – transparent yellow solution.
| 1 amp. | |
| Lornoxicam (calculated on dry substance) | 8 mg |
Excipients: mannitol – 100 mg, trometamol – 12 mg, edetate disodium dihydrate – 0.2 mg.
Solvent: water for injections, solvent for preparation of medicinal forms for injections (ampoules 2 ml).
8 mg – ampoules (5) – contour cell packs (1) – cardboard packs.
8 mg – ampoules (5) – contour cell packs (2) – cardboard packs.
8 mg – ampoules (5) – cardboard packs with corrugated insert.
8 mg – ampoules (5) – cardboard packs with corrugated insert.
8 mg – ampoules (10) – contour cell packs (1) in set with solvent (5 amp. in contour cell pack (1 pcs.)) – cardboard packs.
Lyophilisate for preparation of solution for intravenous and intramuscular administration 8 mg: vial 5 pcs.
Marketing Authorization Holder
Endocrine Technologies, LLC (Russia)
Manufactured By
Ferment Firm, LLC (Russia)
Quality Control Release
MOSCOW ENDOCRINE PLANT, FSUE (Russia)
Dosage Form
|
Lornoxicam | Lyophilisate for preparation of solution for intravenous and intramuscular administration 8 mg: vial 5 pcs. |
Dosage Form, Packaging, and Composition
Lyophilisate for preparation of solution for intravenous and intramuscular administration in the form of a dense powder of yellow color.
| 1 vial | |
| Lornoxicam | 8 mg |
Excipients: mannitol (mannite) – 100 mg, trometamol – 12 mg, edetate disodium – 0.2 mg, sodium hydroxide solution 1M – to pH 8 – 9.5.
Vials (5) – cardboard packs.
Lyophilisate for preparation of solution for intravenous and intramuscular administration 8 mg: vial 1, 5 or 10 pcs.
Marketing Authorization Holder
Canonpharma Production, CJS (Russia)
Manufactured By
Vifitech, CJSC (Russia)
Dosage Form
|
Lornoxicam Canon | Lyophilisate for preparation of solution for intravenous and intramuscular administration 8 mg: vial 1, 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Lyophilisate for preparation of solution for intravenous and intramuscular administration in the form of a dense mass of yellow color.
| 1 vial | |
| Lornoxicam | 8 mg |
Excipients: mannitol – 100 mg, edetate sodium – 0.2 mg, trometamol – 12 mg.
8 mg – vials (1) – cardboard packs.
8 mg – vials (5) – plastic trays – cardboard packs.
8 mg – vials (10) – plastic trays – cardboard packs.
Film-coated tablets, 4 mg: 10, 20, 30, 50, 60, 90, or 100 pcs.
Film-coated tablets, 8 mg: 10, 20, 30, 50, 60, 90, or 100 pcs.
Marketing Authorization Holder
Canonpharma Production, CJS (Russia)
Dosage Forms
|
Lornoxicam Canon | Film-coated tablets, 4 mg: 10, 20, 30, 50, 60, 90, or 100 pcs. |
| Film-coated tablets, 8 mg: 10, 20, 30, 50, 60, 90, or 100 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets yellow, round, biconvex; the cross-section is yellow.
| 1 tab. | |
| Lornoxicam | 4 mg |
Excipients: croscarmellose sodium, lactose monohydrate, magnesium stearate, povidone K-30, microcrystalline cellulose (type 101).
Film coating composition Opadry® 20A220084 yellow: hypromellose (hydroxypropyl methylcellulose), hyprolose (hydroxypropyl cellulose), talc, titanium dioxide, iron oxide red dye, quinoline yellow dye.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
10 pcs. – contour cell packs (9) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
30 pcs. – contour cell packs (1) – cardboard packs.
30 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – contour cell packs (3) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
60 pcs. – polymer jars (1) – cardboard packs.
90 pcs. – polymer jars (1) – cardboard packs.
100 pcs. – polymer jars (1) – cardboard packs.
Film-coated tablets yellow, round, biconvex; the cross-section is yellow.
| 1 tab. | |
| Lornoxicam | 8 mg |
Excipients: croscarmellose sodium, lactose monohydrate, magnesium stearate, povidone K-30, microcrystalline cellulose (type 101).
Film coating composition Opadry® 20A220084 yellow: hypromellose (hydroxypropyl methylcellulose), hyprolose (hydroxypropyl cellulose), talc, titanium dioxide, iron oxide red dye, quinoline yellow dye.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
10 pcs. – contour cell packs (9) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
30 pcs. – contour cell packs (1) – cardboard packs.
30 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – contour cell packs (3) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
60 pcs. – polymer jars (1) – cardboard packs.
90 pcs. – polymer jars (1) – cardboard packs.
100 pcs. – polymer jars (1) – cardboard packs.
Film-coated tablets 4 mg
Film-coated tablets 8 mg
Marketing Authorization Holder
Velpharm, LLC (Russia)
Manufactured By
Velpharm, LLC (Russia)
Or
Velpharm-M, LLC (Russia)
Dosage Forms
|
Lornoxicam Velpharm | Film-coated tablets 4 mg |
| Film-coated tablets 8 mg |
Dosage Form, Packaging, and Composition
Film-coated tablets
| 1 tab. | |
| Lornoxicam | 4 mg |
10 pcs. – jars – cardboard packs (10 pcs.) – By prescription
10 pcs. – contour cell packs – cardboard packs (10 pcs.) – By prescription
10 pcs. – contour cell packs (10 pcs.) – cardboard packs (100 pcs.) – By prescription
10 pcs. – contour cell packs (2 pcs.) – cardboard packs (20 pcs.) – By prescription
10 pcs. – contour cell packs (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – contour cell packs (4 pcs.) – cardboard packs (40 pcs.) – By prescription
10 pcs. – contour cell packs (5 pcs.) – cardboard packs (50 pcs.) – By prescription
10 pcs. – contour cell packs (6 pcs.) – cardboard packs (60 pcs.) – By prescription
10 pcs. – contour cell packs (7 pcs.) – cardboard packs (70 pcs.) – By prescription
10 pcs. – contour cell packs (8 pcs.) – cardboard packs (80 pcs.) – By prescription
10 pcs. – contour cell packs (9 pcs.) – cardboard packs (90 pcs.) – By prescription
100 pcs. – jars – cardboard packs (100 pcs.) – By prescription
14 pcs. – contour cell packs – cardboard packs (14 pcs.) – By prescription
14 pcs. – contour cell packs (10 pcs.) – cardboard packs (140 pcs.) – By prescription
14 pcs. – contour cell packs (2 pcs.) – cardboard packs (28 pcs.) – By prescription
14 pcs. – contour cell packs (3 pcs.) – cardboard packs (42 pcs.) – By prescription
14 pcs. – contour cell packs (4 pcs.) – cardboard packs (56 pcs.) – By prescription
14 pcs. – contour cell packs (5 pcs.) – cardboard packs (70 pcs.) – By prescription
14 pcs. – contour cell packs (6 pcs.) – cardboard packs (84 pcs.) – By prescription
14 pcs. – contour cell packs (7 pcs.) – cardboard packs (98 pcs.) – By prescription
14 pcs. – contour cell packs (8 pcs.) – cardboard packs (112 pcs.) – By prescription
14 pcs. – contour cell packs (9 pcs.) – cardboard packs (126 pcs.) – By prescription
20 pcs. – jars – cardboard packs (20 pcs.) – By prescription
30 pcs. – jars – cardboard packs (30 pcs.) – By prescription
40 pcs. – jars – cardboard packs (40 pcs.) – By prescription
50 pcs. – jars – cardboard packs (50 pcs.) – By prescription
60 pcs. – jars – cardboard packs (60 pcs.) – By prescription
70 pcs. – jars – cardboard packs (70 pcs.) – By prescription
80 pcs. – jars – cardboard packs (80 pcs.) – By prescription
90 pcs. – jars – cardboard packs (90 pcs.) – By prescription
Film-coated tablets
| 1 tab. | |
| Lornoxicam | 8 mg |
10 pcs. – jars – cardboard packs (10 pcs.) – By prescription
10 pcs. – contour cell packs – cardboard packs (10 pcs.) – By prescription
10 pcs. – contour cell packs (10 pcs.) – cardboard packs (100 pcs.) – By prescription
10 pcs. – contour cell packs (2 pcs.) – cardboard packs (20 pcs.) – By prescription
10 pcs. – contour cell packs (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – contour cell packs (4 pcs.) – cardboard packs (40 pcs.) – By prescription
10 pcs. – contour cell packs (5 pcs.) – cardboard packs (50 pcs.) – By prescription
10 pcs. – contour cell packs (6 pcs.) – cardboard packs (60 pcs.) – By prescription
10 pcs. – contour cell packs (7 pcs.) – cardboard packs (70 pcs.) – By prescription
10 pcs. – contour cell packs (8 pcs.) – cardboard packs (80 pcs.) – By prescription
10 pcs. – contour cell packs (9 pcs.) – cardboard packs (90 pcs.) – By prescription
100 pcs. – jars – cardboard packs (100 pcs.) – By prescription
14 pcs. – contour cell packs – cardboard packs (14 pcs.) – By prescription
14 pcs. – contour cell packs (10 pcs.) – cardboard packs (140 pcs.) – By prescription
14 pcs. – contour cell packs (2 pcs.) – cardboard packs (28 pcs.) – By prescription
14 pcs. – contour cell packs (3 pcs.) – cardboard packs (42 pcs.) – By prescription
14 pcs. – contour cell packs (4 pcs.) – cardboard packs (56 pcs.) – By prescription
14 pcs. – contour cell packs (5 pcs.) – cardboard packs (70 pcs.) – By prescription
14 pcs. – contour cell packs (6 pcs.) – cardboard packs (84 pcs.) – By prescription
14 pcs. – contour cell packs (7 pcs.) – cardboard packs (98 pcs.) – By prescription
14 pcs. – contour cell packs (8 pcs.) – cardboard packs (112 pcs.) – By prescription
14 pcs. – contour cell packs (9 pcs.) – cardboard packs (126 pcs.) – By prescription
20 pcs. – jars – cardboard packs (20 pcs.) – By prescription
30 pcs. – jars – cardboard packs (30 pcs.) – By prescription
40 pcs. – jars – cardboard packs (40 pcs.) – By prescription
50 pcs. – jars – cardboard packs (50 pcs.) – By prescription
60 pcs. – jars – cardboard packs (60 pcs.) – By prescription
70 pcs. – jars – cardboard packs (70 pcs.) – By prescription
80 pcs. – jars – cardboard packs (80 pcs.) – By prescription
90 pcs. – jars – cardboard packs (90 pcs.) – By prescription
Lyophilisate for preparation of solution for intravenous and intramuscular administration 8 mg: vial 1, 5 or 10 pcs.
Marketing Authorization Holder
Binergia JSC (Russia)
Manufactured By
Kursk Biopharmaceutical Plant – Firm “Biok”, FKP (Russia)
Dosage Form
|
Lornoxicam-Binergia | Lyophilisate for preparation of solution for intravenous and intramuscular administration 8 mg: vial 1, 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Lyophilisate for preparation of solution for intravenous and intramuscular administration in the form of a dense mass of yellow color; the reconstituted solution is a clear yellow solution.
| 1 vial | |
| Lornoxicam | 8 mg* |
* the amount of lornoxicam, including a 7.5% overage, is 8.6 mg.
Excipients: mannitol – 100 mg, trometamol – 12 mg, disodium edetate – 0.2 mg.
8 mg – vials of light-protective glass (1) – cardboard packs.
8 mg – vials of light-protective glass (5) – cardboard packs.
8 mg – vials of light-protective glass (10) – cardboard packs.
Lyophilisate for preparation of solution for intravenous and intramuscular administration 8 mg: vial 5 or 10 pcs.
Marketing Authorization Holder
Trivium-XXI, LLC (Russia)
Manufactured By
Armavir Biopharmaceutical Plant, FSE (Russia)
Dosage Form
|
Lornoxicam-Trivium® | Lyophilisate for preparation of solution for intravenous and intramuscular administration 8 mg: vial 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Lyophilisate for preparation of solution for intravenous and intramuscular administration in the form of a dense mass of yellow color.
| 1 vial | |
| Lornoxicam | 8 mg |
Excipients: mannitol (mannite) – 100 mg, trometamol – 12 mg, disodium edetate – 0.2 mg.
One ampoule with solvent contains water for injections – 2 ml.
8 mg – vials (5) – cardboard packs.
8 mg – vials (10) – cardboard packs.
8 mg – vials (25) – cardboard boxes (for hospitals).
8 mg – vials (5) – cardboard packs in a set with solvent: water for injections 2 ml amp. 5 pcs..
8 mg – vials (5) – cardboard packs in a set with solvent: water for injections 2 ml amp. 10 pcs..
8 mg – vials (5) – cardboard boxes (for hospitals) in a set with solvent: water for injections 2 ml amp. 25 pcs.
![Lornoxicam [Tablets, Lyophilisate] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Lornoxicam [Tablets, Lyophilisate] 2")